Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025

Matinas BioPharma Holdings, Inc.

2024-Q1 EPS reported -$0.03 vs consensus -$1.53 ▲ beat (+98.0%)

Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).
Cash and equivalents $8.1M at March 31, 2024; subsequent $10M registered direct offering in April 2024.
Active partnership discussions to advance MAT2203 into Phase 3 ORALTO trial in invasive aspergillosis.
Compassionate use program has enrolled 22 patients with severe fungal infections; LNC platform abstracts at ASGCT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.

Period: the three months ending March 31, 2024
Revenue: no revenue for the first quarter of 2024
Net income: net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share
EPS: $0.03 per share
Result: reported results

Exact text from the filing

Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.